Oculis to Participate in Upcoming Investor Conferences

Core Insights - Oculis Holding AG is advancing its position in neuro-ophthalmology and ophthalmology with a late-stage portfolio and significant market opportunities [2][6] - The company has received breakthrough therapy designation for its product Privosegtor, targeting optic neuritis, with a potential market opportunity exceeding $7 billion in the U.S. [2] - Oculis is set to present pivotal trial results for its product OCS-01 in diabetic macular edema (DME) in Q2 2026 [2] - The company is also developing Licaminlimab, a precision medicine approach for dry eye disease (DED) [2][6] Company Overview - Oculis is a global biopharmaceutical company focused on addressing unmet medical needs in neuro-ophthalmology and ophthalmology [6] - The company has a strong balance sheet and a robust pipeline, aiming to deliver six pivotal readouts with current funding [3] - Oculis is headquartered in Switzerland and operates in the U.S. and Iceland, led by an experienced management team [6] Upcoming Events - Oculis management will participate in the Leerink Global Healthcare Conference from March 8-11, with a presentation scheduled for March 10 [4] - The company will also engage in one-on-one meetings at the Leerink Partners Mountain Meeting from March 22-25 [5] - Additional one-on-one meetings are planned during the LifeSci Capital Biotech Forum on March 26 [5]